The motion cites 22 cases, most in California, filed against brand manufacturer Pfizer Inc. and authorized generic providers. The motion says most of the plaintiffs will be in Massachusetts or ...
At a Case Management Conference in the Multi District Litigation against Pfizer Inc. (NYSE:PFE), the Honorable M. Casey Rodgers set a date for the first Trial, which will take place in December 2026, ...
The FDA approved a new safety warning for Depo-Provera alerting patients to a possible risk for a type of brain tumor called meningioma.
Hosted on MSN
Depo Provera brain tumor warning: Why the FDA changed the label and what it means for users
The FDA has approved a critical label change for Pfizer's widely used Depo-Provera birth control injection, adding a warning about the risk of meningioma—a typically non-cancerous but potentially ...
Medroxyprogesterone acetate 104mg/0.65mL; SC inj; contains parabens. Medroxyprogesterone acetate inhibits the secretion of gonadotropins which primarily prevents follicular maturation and ovulation ...
Teva Pharmaceutical Industries Ltd., TEVA announced the reintroduction of the generic equivalent to Depo-Prover Contraceptive Injection (medroxyprogesterone acetate injectable suspension, USP) 150 ...
For many African women, the generic version of the hormonal birth control shot Depo-Provera is a godsend. Just one injection every three months allows them to know with near-100 percent certainty that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback